Literature DB >> 11517397

HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years.

T Matsuzaki1, M Nakagawa, M Nagai, K Usuku, I Higuchi, K Arimura, H Kubota, S Izumo, S Akiba, M Osame.   

Abstract

To clarify clinical and laboratory findings that may be related to the pathomechanism of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), we analyzed these findings in 239 patients with HAM/TSP, including 64 patients followed up for 10 years after their first examinations, with special interest in the HTLV-I proviral load in peripheral blood mononuclear cells (PBMCs). The proviral load in PBMCs did not differ in terms of modes of HTLV-I transmission. However, the proviral load in patients with age of disease onset greater than 65 years tended to be higher than those with a younger age of onset. In the 64 patients followed up for 10 years, the clinical symptoms deteriorated in 36 patients (56%), unchanged in 26 patients (41%), and improved in 2 patients (3%). HTLV-I proviral load also appeared to be related to the deterioration of motor disability in these patients. To our knowledge, the present study is the first longitudinal study concerning the relationship between the clinical course of HAM/TSP and HTLV-I proviral load. It is suggested that HTLV-I proviral load is related to the progression of motor disability and is an important factor to predict prognosis of patients with HAM/TSP.

Entities:  

Mesh:

Year:  2001        PMID: 11517397     DOI: 10.1080/13550280152403272

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  23 in total

1.  Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP.

Authors:  M Nagai; K Usuku; W Matsumoto; D Kodama; N Takenouchi; T Moritoyo; S Hashiguchi; M Ichinose; C R Bangham; S Izumo; M Osame
Journal:  J Neurovirol       Date:  1998-12       Impact factor: 2.643

2.  HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings.

Authors:  M Nakagawa; S Izumo; S Ijichi; H Kubota; K Arimura; M Kawabata; M Osame
Journal:  J Neurovirol       Date:  1995-03       Impact factor: 2.643

3.  Quantification of HTLV-1 proviral copy number in peripheral blood of symptomless carriers from the French West Indies.

Authors:  E Wattel; M Mariotti; F Agis; E Gordien; F F Le Coeur; L Prin; P Rouger; I S Chen; S Wain-Hobson; J J Lefrere
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

4.  Increased replication of HTLV-I in HTLV-I-associated myelopathy.

Authors:  M Yoshida; M Osame; H Kawai; M Toita; N Kuwasaki; Y Nishida; Y Hiraki; K Takahashi; K Nomura; S Sonoda
Journal:  Ann Neurol       Date:  1989-09       Impact factor: 10.422

5.  HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T-cell leukemia/lymphoma.

Authors:  K Usuku; S Sonoda; M Osame; S Yashiki; K Takahashi; M Matsumoto; T Sawada; K Tsuji; M Tara; A Igata
Journal:  Ann Neurol       Date:  1988       Impact factor: 10.422

6.  HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy.

Authors:  K J Jeffery; K Usuku; S E Hall; W Matsumoto; G P Taylor; J Procter; M Bunce; G S Ogg; K I Welsh; J N Weber; A L Lloyd; M A Nowak; M Nagai; D Kodama; S Izumo; M Osame; C R Bangham
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

7.  Fluctuation of HTLV-I proviral DNA in peripheral blood mononuclear cells of HTLV-I-associated myelopathy.

Authors:  R Kubota; T Fujiyoshi; S Izumo; S Yashiki; I Maruyama; M Osame; S Sonoda
Journal:  J Neuroimmunol       Date:  1993-02       Impact factor: 3.478

8.  The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I.

Authors:  J E Kaplan; M Osame; H Kubota; A Igata; H Nishitani; Y Maeda; R F Khabbaz; R S Janssen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

9.  Quantitative in situ PCR assay of HTLV-1 infected cells in peripheral blood lymphocytes of patients with ATL, HAM/TSP and asymptomatic carriers.

Authors:  K Hashimoto; I Higuchi; M Osame; S Izumo
Journal:  J Neurol Sci       Date:  1998-07-15       Impact factor: 3.181

Review 10.  Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I).

Authors:  A Gessain; O Gout
Journal:  Ann Intern Med       Date:  1992-12-01       Impact factor: 25.391

View more
  60 in total

1.  Multiplex Droplet Digital PCR Assay for Quantification of Human T-Cell Leukemia Virus Type 1 Subtype c DNA Proviral Load and T Cells from Blood and Respiratory Exudates Sampled in a Remote Setting.

Authors:  David Yurick; Georges Khoury; Bridie Clemens; Liyen Loh; Hai Pham; Katherine Kedzierska; Lloyd Einsiedel; Damian Purcell
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

Review 2.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

3.  Genetic variability in the extracellular matrix protein as a determinant of risk for developing HTLV-I-associated neurological disease.

Authors:  Yasuyuki Nobuhara; Koichiro Usuku; Mineki Saito; Shuji Izumo; Kimiyoshi Arimura; Charles R M Bangham; Mitsuhiro Osame
Journal:  Immunogenetics       Date:  2006-01-10       Impact factor: 2.846

4.  Accumulation of human T-lymphotropic virus type I (HTLV-I)-infected cells in the cerebrospinal fluid during the exacerbation of HTLV-I-associated myelopathy.

Authors:  Daisuke Hayashi; Ryuji Kubota; Norihiro Takenouchi; Tomonori Nakamura; Fujio Umehara; Kimiyoshi Arimura; Shuji Izumo; Mitsuhiro Osame
Journal:  J Neurovirol       Date:  2008-11-12       Impact factor: 2.643

5.  Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.

Authors:  Reza Boostani; Rosita Vakili; Samane Sadat Hosseiny; Ali Shoeibi; Bahare Fazeli; Mohammad Mehdi Etemadi; Faeze Sabet; Narges Valizade; Seyed Abdolrahim Rezaee
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

6.  Immunological and viral features in patients with overactive bladder associated with human T-cell lymphotropic virus type 1 infection.

Authors:  Silvane Braga Santos; Paulo Oliveira; Tania Luna; Anselmo Souza; Márcia Nascimento; Isadora Siqueira; Davi Tanajura; André Luiz Muniz; Marshall J Glesby; Edgar M Carvalho
Journal:  J Med Virol       Date:  2012-11       Impact factor: 2.327

7.  Acute human T-lymphotropic virus type I-associated myelitis: a rare case successfully treated with intravenous pulse methylprednisolone.

Authors:  Reza Boostani; Ali Ghabeli Juibary
Journal:  J Neurovirol       Date:  2014-05-28       Impact factor: 2.643

Review 8.  Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control.

Authors:  Charles R M Bangham
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

9.  Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Marco A Lima; Ramza C Harab; Doris Schor; Maria J Andrada-Serpa; Abelardo Q C Araújo
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

10.  Is human T cell lymphotropic type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) syndrome a neglected disease?

Authors:  Jorge Casseb
Journal:  PLoS Negl Trop Dis       Date:  2009-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.